|

Cobimetinib Clinical Trials

6 actively recruiting trials across 3 locations

No change since May 2026

Also known as: COTELLIC, Cotellic, Cotellic®, GDC 0973, GDC-0973 +6 more

Pipeline

Early 1: 1Phase 2: 4Phase 2/3: 1

Top Sponsors

  • OHSU Knight Cancer Institute1
  • Helsinki University Central Hospital1
  • Genentech, Inc.1
  • City of Hope Medical Center1
  • Carl Allen1

Indications

  • Cancer6
  • Lung Cancer3
  • Erdheim-Chester Disease2
  • Haematological Malignancy2
  • Thyroid Carcinoma, Anaplastic1

Other2 trials

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Phase 2/3
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Duarte, California2 trials

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2

Phoenix, Arizona1 trial

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Phoenix Children's Hospital

Phase 2

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.